Monopar Therapeutics (MNPR) Net Cash Flow: 2017-2020
Historic Net Cash Flow for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to $5.4 million.
- Monopar Therapeutics' Net Cash Flow rose 967.33% to $5.4 million in Q3 2020 from the same period last year, while for Sep 2020 it was $13.5 million, marking a year-over-year increase of 533.08%. This contributed to the annual value of $38.5 million for FY2024, which is 4367.57% up from last year.
- According to the latest figures from Q3 2020, Monopar Therapeutics' Net Cash Flow is $5.4 million, which was up 11,174.54% from -$49,070 recorded in Q2 2020.
- Monopar Therapeutics' Net Cash Flow's 5-year high stood at $8.7 million during Q4 2019, with a 5-year trough of -$1.0 million in Q1 2019.
- In the last 3 years, Monopar Therapeutics' Net Cash Flow had a median value of -$626,549 in 2019 and averaged $746,423.
- Per our database at Business Quant, Monopar Therapeutics' Net Cash Flow plummeted by 219.21% in 2018 and then skyrocketed by 1,301.71% in 2019.
- Quarterly analysis of 4 years shows Monopar Therapeutics' Net Cash Flow stood at -$806,020 in 2017, then climbed by 9.99% to -$725,482 in 2018, then surged by 1,301.71% to $8.7 million in 2019, then soared by 967.33% to $5.4 million in 2020.
- Its last three reported values are $5.4 million in Q3 2020, -$49,070 for Q2 2020, and -$617,526 during Q1 2020.